AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:26 2024-09-13 am EDT			5-day change	1st Jan Change
11,928.00 ^GBX	-1.01%		-5.71%	+12.53%

Sep. 13	AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	MT
Sep. 13	Daiichi, Astra's Enhertu shows clinical activity in brain metastases	AN

ASTRAZENECA : Gets a Sell rating from UBS

August 13, 2024 at 08:56 am EDT

In his latest research note, analyst Matthew Weston confirms his negative recommendation. The broker UBS is keeping its Sell rating. The target price remains set at GBX 11300.

Latest news about AstraZeneca PLC

AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	Sep. 13	MT
Daiichi, Astra's Enhertu shows clinical activity in brain metastases	Sep. 13	AN
Stocks up as market raises bets on bumper US cut	Sep. 13	AN
AstraZeneca, Daiichi Sankyo Reports Safety Profile of Breast Cancer Drug in Phase 3b/4 Study	Sep. 13	MT
Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases	Sep. 13	CI
A central bank and it's off again?	Sep. 13
Deutsche Bank Downgrades AstraZeneca to Sell From Hold	Sep. 13	MT
ASTRAZENECA : Deutsche Bank upgrades to 'sell'.	Sep. 13	CF
Deutsche Bank Downgrades AstraZeneca to Sell, Trims PT	Sep. 13	MT
Gold miners shine but AstraZeneca curbs progress	Sep. 13	AN
AstraZeneca downgraded by Deutsche Bank	Sep. 13	CF
ASTRAZENECA : Deutsche Bank downgrades from Neutral to Sell	Sep. 13	ZD
Deutsche Bank cuts AstraZeneca to 'sell'	Sep. 13	AN
Stocks rise and gold gleams as eyes turn to Fed	Sep. 13	AN
European shares climb with focus on US cenbank policy decision	Sep. 13	RE
UK scrutiny for Vodafone-Three; Flutter in Brazil bet	Sep. 13	AN
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Sep. 12	MT
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma	Sep. 12	CI
AlphaValue/Baader Europe Upgrades AstraZeneca to Add, Lifts PT	Sep. 11	MT
Nordea Bank Downgrades AstraZeneca to Sell	Sep. 11	MT
The mood is getting heavier, but Taylor Swift is keeping watch	Sep. 11
FTSE 100 in uninspiring gain before US data	Sep. 11	AN
ASTRAZENECA : Set to conquer new highs backed by ambitious goals	Sep. 11
AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	Sep. 10	MT
European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	Sep. 10	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-09-15 - European Society for Medical Oncology Meeting - Abstract No #431P

More about the company